Evaluation of Sentinel Node Biopsy in Locally Advanced Breast Cancer Patients Who Become Clinically Node-Negative after Neoadjuvant Chemotherapy: A Preliminary StudyReport as inadecuate




Evaluation of Sentinel Node Biopsy in Locally Advanced Breast Cancer Patients Who Become Clinically Node-Negative after Neoadjuvant Chemotherapy: A Preliminary Study - Download this document for free, or read online. Document in PDF available to download.

International Journal of Breast CancerVolume 2011 2011, Article ID 870263, 6 pages

Research Article

Departments of Surgery and Pathology, Lady Hardinge Medical College, Shaheed Bhagat Singh Marg, New Delhi 110001, India

Department of Radiological Imaging, Institute of Nuclear Medicine and Allied Sciences, Delhi 110054, India

Received 18 April 2011; Revised 9 August 2011; Accepted 11 August 2011

Academic Editor: Luciane R. Cavalli

Copyright © 2011 Shaji Thomas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction. Controversy continues over the appropriate timing of sentinel lymph node SLN biopsy in locally advanced breast cancer LABC patients receiving neoadjuvant chemotherapy. We evaluated the feasibility and accuracy of SLN biopsy in LABC patients with cytology-proven axillary nodal metastasis who become clinically node-negative after neoadjuvant chemotherapy. Materials. 30 consecutive patients with LABC, who had become clinically node-negative after 3 cycles of neoadjuvant chemotherapy, were included in the study. They were then subjected to SLN biopsy, axillary lymph node dissection, and breast surgery. Results. Sentinel nodes were successfully identified in 26 of the 30 patients, resulting in an identification rate of 86.67%, sensitivity of 83.33%, false negative rate of 20%, negative predictive value of 72.73%, and an overall accuracy of 88.46%. No complications were observed as a result of dye injection. Conclusions. SLN biopsy is feasible and safe in LABC patients with cytology-positive nodes who become clinically node-negative after neoadjuvant chemotherapy. Our accuracy rate, identification rate, and false negative rate are comparable to those in node-negative LABC patients. SLN biopsy as a therapeutic option in LABC after neoadjuvant chemotherapy is a promising option which should be further investigated.





Author: Shaji Thomas, Apurva Prakash, Vinay Goyal, Manju Bala Popli, Shilpi Agarwal, and Monisha Choudhury

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents